-
Three HIV/AIDS activist groups convened a meeting in March with researchers and representatives of the U.S. Food and Drug Administration (FDA) to describe the current state of cure research and identify barriers to moving such research forward swiftly and smoothly. The proceedings of this meeting, which took place immediately before the 19th Conference on Retroviruses and Opportunistic Infections (CROI) that began on March 5 in Seattle, are now available in a report online.
26 April 2012 | AIDSMeds
-
Tim Gowers, a mathematician at Cambridge University, has hit a nerve with academics who are increasingly fed up with the stranglehold that a few publishing companies have gained over the publication and distribution of the world's scientific research.
10 April 2012 | The Guardian
-
Despite outrage from activists, Merck refused to study drug-drug interactions (DDIs) between boceprevir (Victrelis), their HCV protease inhibitor, and drugs commonly used to treat HIV, putting coinfected study volunteers at risk for drug-drug interactions in their own clinical trial.
10 April 2012 | TAG
-
At the Food and Drug Administration (FDA) advisory hearing on Thursday, February 9, a panel of scientists and clinicians voted unanimously not to recommend approval of the Qutenza capsaicin patch for HIV neuropathy pain, based on data from 2 clinical trials. As the sole patient representative on the panel, it was an incredibly demoralizing experience.
20 February 2012 | HIVandHepatitis.com
-
We face a new scientific challenge: how to demonstrate the
safety and efficacy of promising new antiretroviral drugs when the two
traditional study designs – the superiority trial and the
non-inferiority trial – are no longer useful in showing improvements in
both “treatment experienced” patients and those who have never received
drug therapy (treatment-naïve patients).
07 February 2012 | Forum for Collaborative HIV Research
-
Lengthy, complicated documents leave many clinical-trial participants in the dark about the risks they face.
06 February 2012 | Nature
-
Pfizer, the world’s largest drug maker, is preparing to test a "virtual’’
clinical trial which would allow patients to participate from their homes,
eliminating the time and expense of traveling to medical schools or other study
sites.
17 January 2012 | NJ.com
-
We write as people with HIV and community activists with serious and
unresolved concerns about the proposed clinical trial comparing
stavudine at 20 mg to tenofovir.
20 December 2011 | Treatment Action Group
-
Leaders of several HIV clinical trial networks shared information about
the respective missions and agendas of these vital research consortia in
one of the opening sessions at the Infectious Diseases Society of
America 49th Annual Meeting.
20 October 2011 | Science Speaks
-
Human testing is a global game dominated by corporations, called contract research
organizations (CROs), that help Big Pharma bring new molecules from the
lab to your medicine cabinet.
28 September 2011 | The Nation
Talking points: a checklist for you and your doctorTalking points is designed to help you talk to your doctor about HIV
treatment.
Preventing HIVAn essential resource providing evidence-based information on preventing HIV infection. 
HIV, stigma and discrimination is now available in print!17 May 2012This week, boxes of the brand-new edition of our booklet...
Come and see us at the BHIVA conference!18 April 2012This morning, I boarded a train at Euston with one...
Community action on harm reduction (CAHR)16 April 2012We’ve been working on the design and
development of a new...